IBio Inc

iBio’s new ownership shift: director Stoner Elizabeth increases stake in plant‑based biotech firm, raising hopes for a turnaround amid financial struggles.

Explore iBio’s pioneering plant‑based biotech strategy, its current stock trends, and the high‑risk, high‑reward potential for breakthrough infectious disease treatments.

iBio’s 8‑K amendment updates Series G warrants and launches the first‑in‑human Phase 1 trial of plant‑made IBIO‑600, promising new hope for serious infectious diseases.

iBio, Inc. navigates biotech volatility while pioneering plant-made vaccines for serious infections—financial hurdles, niche focus, and future potential explored.

iBio Inc.